Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Benjamin M. Ellingson, Martin Bendszus, Jerrold Boxerman, Daniel Barboriak, Bradley J. Erickson, Marion Smits, Sarah J. Nelson, Elizabeth Gerstner, Brian Alexander, Gregory Goldmacher, Wolfgang Wick, Michael Vogelbaum, Michael Weller, Evanthia Galanis, Jayashree Kalpathy-Cramer, Lalitha Shankar, Paula Jacobs, Whitney B. Pope, Dewen Yang, Caroline ChungMichael V. Knopp, Soonme Cha, Martin J. Van Den Bent, Susan Chang, W. K. Al Yung, Timothy F. Cloughesy, Patrick Y. Wen, Mark R. Gilbert, Andrew Whitney, David Sandak, Al Musella, Chas Haynes, Max Wallace, David F. Arons, Ann Kingston

Research output: Contribution to journalReview article

168 Scopus citations

Abstract

A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.

Original languageEnglish (US)
Pages (from-to)1188-1198
Number of pages11
JournalNeuro-Oncology
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2015

Keywords

  • Brain Tumor Imaging Protocol
  • MRI
  • clinical trials
  • glioblastoma

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials'. Together they form a unique fingerprint.

  • Cite this

    Ellingson, B. M., Bendszus, M., Boxerman, J., Barboriak, D., Erickson, B. J., Smits, M., Nelson, S. J., Gerstner, E., Alexander, B., Goldmacher, G., Wick, W., Vogelbaum, M., Weller, M., Galanis, E., Kalpathy-Cramer, J., Shankar, L., Jacobs, P., Pope, W. B., Yang, D., ... Kingston, A. (2015). Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology, 17(9), 1188-1198. https://doi.org/10.1093/neuonc/nov095